| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | AWAL, BEC1, TMVCF, CPETRL1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CLDN5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CLDN5抗体的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: *Claudin-5 regulates blood-brain barrier permeability in Alzheimer's disease models*
**作者**: Smith A, et al.
**摘要**: 本研究利用CLDN5特异性抗体，通过免疫组化和Western blot分析阿尔茨海默病小鼠模型中血脑屏障完整性的变化。结果表明，CLDN5表达降低与β-淀粉样蛋白沉积相关，提示其屏障功能受损可能加剧神经退行性病变。
2. **文献名称**: *CLDN5 antibody-based detection of endothelial tight junction disruption in sepsis*
**作者**: Chen L, et al.
**摘要**: 通过CLDN5抗体标记人脐静脉内皮细胞(HUVECs)，研究脓毒症炎症因子(如TNF-α)对紧密连接的影响。免疫荧光显示CLDN5分布紊乱，屏障通透性显著增加，为靶向CLDN5的治疗策略提供依据。
3. **文献名称**: *CLDN5 as a biomarker for metastatic breast cancer progression*
**作者**: Gupta R, et al.
**摘要**: 采用CLDN5抗体分析乳腺癌组织中内皮细胞标志物的表达，发现CLDN5在转移性肿瘤血管中异常高表达，可能促进癌细胞外渗。研究提示CLDN5抗体可用于评估肿瘤侵袭性。
4. **文献名称**: *Development and validation of a novel anti-CLDN5 monoclonal antibody for neurovascular research*
**作者**: Tanaka K, et al.
**摘要**: 报道一种高特异性兔源CLDN5单克隆抗体的制备，并通过流式细胞术、免疫印迹验证其可靠性。该抗体成功应用于脑微血管内皮细胞的体外屏障模型构建。
---
注：以上文献为模拟内容，实际研究中建议通过PubMed、Google Scholar等平台检索真实文献(关键词：CLDN5 antibody, blood-brain barrier, endothelial junction等)。
The CLDN5 antibody is a crucial tool for studying claudin-5 (CLDN5), a member of the claudin family of transmembrane proteins that form tight junctions between epithelial and endothelial cells. Primarily expressed in vascular endothelial cells, CLDN5 is a key component of the blood-brain barrier (BBB), regulating paracellular permeability and maintaining homeostasis in the central nervous system. Its selective expression in the BBB makes it a biomarker for studying neurological disorders, including stroke, Alzheimer’s disease, and brain tumors. Dysregulation of CLDN5 has also been linked to cancer metastasis, as altered tight junction integrity may facilitate tumor cell invasion.
CLDN5 antibodies are widely used in immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to visualize protein localization, expression levels, and structural integrity in tissue samples or cultured cells. These antibodies aid in assessing BBB disruption in neurodegenerative diseases or evaluating vascular changes in tumors. Researchers also utilize CLDN5 antibodies in functional studies to explore its role in cell-cell adhesion, barrier formation, and signaling pathways. Commercially available antibodies are typically raised against specific epitopes of human or murine CLDN5. with validation across multiple applications. However, cross-reactivity with other claudin family members (e.g., CLDN3 or CLDN12) remains a consideration, necessitating careful validation. Overall, CLDN5 antibodies are indispensable for advancing research in neurobiology, oncology, and vascular biology.
×
